{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T19:10:03Z","timestamp":1792696203538,"version":"4.5.0"},"reference-count":48,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,8,30]],"date-time":"2023-08-30T00:00:00Z","timestamp":1693353600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Aging Neurosci."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Progressive supranuclear palsy (PSP) is a clinically heterogenous atypical parkinsonian syndrome. Therefore, early recognition and correct diagnosis of PSP is challenging but essential. This study aims to characterize the clinical manifestations, magnetic resonance imaging (MRI), and longitudinal MRI changes of PSP in China.<\/jats:p><\/jats:sec><jats:sec><jats:title>Method<\/jats:title><jats:p>Clinical and MRI presentations were compared among 150 cases with PSP. Then the longitudinal MRI changes among 20 patients with PSP were further explored. Additionally, a series of midbrain-based MRI parameters was compared between PSP-P and PD.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Throughout the course of the disease, there were differences in the symptoms of the fall and hand tremor between the PSP-RS and PSP-P. There were significant differences in the six midbrain-based MRI parameters between the PSP-RS and the PSP-P, including hummingbird sign, midbrain diameter, midbrain to pons ratio (MTPR), midbrain area, midbrain area to pons area ratio (Ma\/Pa), and midbrain tegmental length (MBTegm). Longitudinal MRI studies revealed that the annual rel.\u0394MTPR and rel.\u0394 (Ma\/Pa) for PSP were 5.55 and 6.52%, respectively; additionally, PSP-RS presented a higher decline rate than PSP-P. Moreover, MTPR \u22640.56, midbrain diameter\u2009\u2264\u20090.92, midbrain area\u2009\u2264\u20091.00, and third ventricle width\u2009\u2264\u20090.75 could identify PSP-P from PD.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>PSP-P differs from PSP-RS regarding clinical manifestations, MRI, and longitudinal MRI changes. MRI parameters could be potential imaging markers to identify PSP-P from PD.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fnagi.2023.1229491","type":"journal-article","created":{"date-parts":[[2023,8,31]],"date-time":"2023-08-31T04:53:11Z","timestamp":1693457591000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":12,"title":["Clinical features of progressive supranuclear palsy"],"prefix":"10.3389","volume":"15","author":[{"given":"Yafei","family":"Wen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qijie","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Jiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiwei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyi","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Weng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinxin","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yafang","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junling","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jifeng","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinxiang","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beisha","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,8,30]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1002\/mds.27619","article-title":"Sensitivity and specificity of diagnostic criteria for progressive Supranuclear palsy","volume":"34","author":"Ali","year":"2019","journal-title":"Mov. Disord."},{"key":"ref2","doi-asserted-by":"publisher","first-page":"180","DOI":"10.3389\/fneur.2020.00180","article-title":"Progressive Supranuclear palsy-parkinsonism predominant (PSP-P)-a clinical challenge at the boundaries of PSP and Parkinson's disease (PD)","volume":"11","author":"Alster","year":"2020","journal-title":"Front. Neurol."},{"key":"ref3","doi-asserted-by":"publisher","first-page":"2421","DOI":"10.3390\/diagnostics12102421","article-title":"The assessment of subregions in the frontal lobe may be feasible in the differential diagnosis of progressive Supranuclear palsy-parkinsonism predominant (PSP-P) and multiple system atrophy (MSA)","volume":"12","author":"Alster","year":"2022","journal-title":"Diagnostics"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1007\/s11910-018-0819-5","article-title":"Progressive Supranuclear palsy: an update","volume":"18","author":"Armstrong","year":"2018","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"ref5","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/S1474-4422(17)30157-6","article-title":"Advances in progressive supranuclear palsy: new diagnostic criteria, biomarkers, and therapeutic approaches","volume":"16","author":"Boxer","year":"2017","journal-title":"Lancet Neurol."},{"key":"ref6","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1097\/WCO.0000000000001035","article-title":"Overview of tau PET molecular imaging","volume":"35","author":"Cassinelli Petersen","year":"2022","journal-title":"Curr. Opin. Neurol."},{"key":"ref7","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1136\/jnnp.2009.195719","article-title":"Survival in progressive supranuclear palsy and frontotemporal dementia","volume":"81","author":"Chiu","year":"2010","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1186\/s12883-020-01692-6","article-title":"Midbrain\/pons area ratio and clinical features predict the prognosis of progressive Supranuclear palsy","volume":"20","author":"Cui","year":"2020","journal-title":"BMC Neurol."},{"key":"ref9","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1111\/j.1750-3639.2007.00054.x","article-title":"Progressive supranuclear palsy: pathology and genetics","volume":"17","author":"Dickson","year":"2007","journal-title":"Brain Pathol."},{"key":"ref10","doi-asserted-by":"publisher","first-page":"2016","DOI":"10.1212\/WNL.0000000000003305","article-title":"Progression of brain atrophy in PSP and CBS over 6 months and 1 year","volume":"87","author":"Dutt","year":"2016","journal-title":"Neurology"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1080\/01616412.2018.1541115","article-title":"MRI evaluation of progressive supranuclear palsy: differentiation from Parkinson's disease and multiple system atrophy","volume":"41","author":"Eraslan","year":"2019","journal-title":"Neurol. Res."},{"key":"ref12","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","article-title":"Mini-mental state. A practical method for grading the cognitive state of patients for the clinician","volume":"12","author":"Folstein","year":"1975","journal-title":"J. Psychiatr. Res."},{"key":"ref13","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1136\/jnnp-2016-314956","article-title":"Predictors of survival in progressive supranuclear palsy and multiple system atrophy: a systematic review and meta-analysis","volume":"88","author":"Glasmacher","year":"2017","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1002\/mds.27666","article-title":"How to apply the movement disorder society criteria for diagnosis of progressive supranuclear palsy","volume":"34","author":"Grimm","year":"2019","journal-title":"Mov. Disord."},{"key":"ref15","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1002\/mds.26987","article-title":"Clinical diagnosis of progressive supranuclear palsy: the movement disorder society criteria","volume":"32","author":"H\u00f6glinger","year":"2017","journal-title":"Mov. Disord."},{"key":"ref16","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1159\/000448174","article-title":"Differential progression of midbrain atrophy in parkinsonism: longitudinal MRI study","volume":"17","author":"Hwang","year":"2017","journal-title":"Neurodegener Dis"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1001\/jamaneurol.2019.4347","article-title":"Diagnosis across the Spectrum of progressive Supranuclear palsy and Corticobasal syndrome","volume":"77","author":"Jabbari","year":"2020","journal-title":"JAMA Neurol."},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1002\/mds.27786","article-title":"The genetic and clinico-pathological profile of early-onset progressive supranuclear palsy","volume":"34","author":"Jabbari","year":"2019","journal-title":"Mov. Disord."},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1007\/s00415-014-7384-x","article-title":"Clinical outcomes of two main variants of progressive supranuclear palsy and multiple system atrophy: a prospective natural history study","volume":"261","author":"Jecmenica-Lukic","year":"2014","journal-title":"J. Neurol."},{"key":"ref20","doi-asserted-by":"publisher","first-page":"2451","DOI":"10.1007\/s00415-022-11556-3","article-title":"Tau PET imaging in progressive supranuclear palsy: a systematic review and meta-analysis","volume":"270","author":"Jin","year":"2023","journal-title":"J. Neurol."},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1007\/s00415-020-10327-2","article-title":"Investigating the 1-year decline in midbrain-to-pons ratio in the differential diagnosis of PSP and IPD","volume":"268","author":"Kannenberg","year":"2021","journal-title":"J. Neurol."},{"key":"ref22","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S0022-510X(03)00014-5","article-title":"Study of the rostral midbrain atrophy in progressive supranuclear palsy","volume":"210","author":"Kato","year":"2003","journal-title":"J. Neurol. Sci."},{"key":"ref23","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1038\/s41380-018-0342-8","article-title":"Tau PET imaging in neurodegenerative tauopathies-still a challenge","volume":"24","author":"Leuzy","year":"2019","journal-title":"Mol. Psychiatry"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"3","DOI":"10.14802\/jmd.15060","article-title":"Clinical approach to progressive Supranuclear palsy","volume":"9","author":"Ling","year":"2016","journal-title":"J Mov Disord."},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1212\/WNL.47.1.1","article-title":"Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop","volume":"47","author":"Litvan","year":"1996","journal-title":"Neurology"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"2701","DOI":"10.3390\/jcm11102701","article-title":"Is MRPI 2.0 more useful than MRPI and M\/P ratio in differential diagnosis of PSP-P with other atypical Parkinsonisms?","volume":"11","author":"Madetko","year":"2022","journal-title":"J. Clin. Med."},{"key":"ref27","doi-asserted-by":"publisher","first-page":"3022","DOI":"10.3390\/diagnostics12123022","article-title":"The use of cerebellar Hypoperfusion assessment in the differential diagnosis of multiple system atrophy with parkinsonism and progressive Supranuclear palsy-parkinsonism predominant","volume":"12","author":"Madetko-Alster","year":"2022","journal-title":"Diagnostics"},{"key":"ref28","first-page":"357","article-title":"Gender differences in progressive supranuclear palsy","volume-title":"Acta Neurol Belg.","author":"Mahale","year":"2022"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1002\/mds.20916","article-title":"Metric attributes of the unified Parkinson's disease rating scale 3.0 battery: part I, feasibility, scaling assumptions, reliability, and precision","volume":"21","author":"Martinez-Martin","year":"2006","journal-title":"Mov. Disord."},{"key":"ref30","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1212\/WNL.0b013e318292a2d2","article-title":"The midbrain to pons ratio: a simple and specific MRI sign of progressive supranuclear palsy","volume":"80","author":"Massey","year":"2013","journal-title":"Neurology"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1002\/mds.23529","article-title":"Accuracy of magnetic resonance parkinsonism index for differentiation of progressive supranuclear palsy from probable or possible Parkinson disease","volume":"26","author":"Morelli","year":"2011","journal-title":"Mov. Disord."},{"key":"ref32","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1111\/j.1532-5415.2005.53221.x","article-title":"The Montreal cognitive assessment, MoCA: a brief screening tool for mild cognitive impairment","volume":"53","author":"Nasreddine","year":"2005","journal-title":"J. Am. Geriatr. Soc."},{"key":"ref33","doi-asserted-by":"publisher","first-page":"2050","DOI":"10.1212\/01.WNL.0000165960.04422.D0","article-title":"New and reliable MRI diagnosis for progressive supranuclear palsy","volume":"64","author":"Oba","year":"2005","journal-title":"Neurology"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1093\/brain\/awn065","article-title":"Clinical outcomes of progressive supranuclear palsy and multiple system atrophy","volume":"131","author":"O'Sullivan","year":"2008","journal-title":"Brain"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.1007\/s00415-016-8278-x","article-title":"The clinical spectrum and natural history of pure akinesia with gait freezing","volume":"263","author":"Owens","year":"2016","journal-title":"J. Neurol."},{"key":"ref36","doi-asserted-by":"publisher","first-page":"603161","DOI":"10.3389\/fneur.2020.603161","article-title":"Association of MRI measures with disease severity and progression in progressive Supranuclear palsy","volume":"11","author":"Picillo","year":"2020","journal-title":"Front. Neurol."},{"key":"ref37","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1002\/mds.26424","article-title":"MDS clinical diagnostic criteria for Parkinson's disease","volume":"30","author":"Postuma","year":"2015","journal-title":"Mov. Disord."},{"key":"ref38","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1002\/mds.28992","article-title":"Development and validation of automated magnetic resonance parkinsonism index 2.0 to distinguish progressive Supranuclear palsy-parkinsonism from Parkinson's disease","volume":"37","author":"Quattrone","year":"2022","journal-title":"Mov. Disord."},{"key":"ref39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.parkreldis.2020.01.019","article-title":"Magnetic resonance parkinsonism index for evaluating disease progression rate in progressive supranuclear palsy: a longitudinal 2-year study","volume":"72","author":"Quattrone","year":"2020","journal-title":"Parkinsonism Relat. Disord."},{"key":"ref40","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1002\/mds.27621","article-title":"Refining initial diagnosis of Parkinson's disease after follow-up: a 4-year prospective clinical and magnetic resonance imaging study","volume":"34","author":"Quattrone","year":"2019","journal-title":"Mov. Disord."},{"key":"ref41","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1212\/WNL.0000000000003125","article-title":"MR parkinsonism index predicts vertical supranuclear gaze palsy in patients with PSP-parkinsonism","volume":"87","author":"Quattrone","year":"2016","journal-title":"Neurology"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1002\/mds.27034","article-title":"Which ante mortem clinical features predict progressive supranuclear palsy pathology?","volume":"32","author":"Respondek","year":"2017","journal-title":"Mov. Disord."},{"key":"ref43","doi-asserted-by":"publisher","first-page":"1758","DOI":"10.1002\/mds.26054","article-title":"The phenotypic spectrum of progressive supranuclear palsy: a retrospective multicenter study of 100 definite cases","volume":"29","author":"Respondek","year":"2014","journal-title":"Mov. Disord."},{"key":"ref44","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1002\/mds.27788","article-title":"One decade ago, one decade ahead in progressive supranuclear palsy","volume":"34","author":"Stamelou","year":"2019","journal-title":"Mov. Disord."},{"key":"ref45","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1001\/archneur.1964.00460160003001","article-title":"Progressive SUPRANUCLEAR palsy. A heterogeneous degeneration involving the BRAIN stem, basal ganglia and cerebellum with vertical gaze and pseudobulbar palsy, nuchal dystonia and dementia","volume":"10","author":"Steele","year":"1964","journal-title":"Arch. Neurol."},{"key":"ref46","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.parkreldis.2011.10.013","article-title":"Rates of brain atrophy and clinical decline over 6 and 12-month intervals in PSP: determining sample size for treatment trials","volume":"18","author":"Whitwell","year":"2012","journal-title":"Parkinsonism Relat. Disord."},{"key":"ref47","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1093\/brain\/awh488","article-title":"Characteristics of two distinct clinical phenotypes in pathologically proven progressive supranuclear palsy: Richardson's syndrome and PSP-parkinsonism","volume":"128","author":"Williams","year":"2005","journal-title":"Brain J. Neurol."},{"key":"ref48","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1093\/brain\/awm104","article-title":"Pathological tau burden and distribution distinguishes progressive supranuclear palsy-parkinsonism from Richardson's syndrome","volume":"130","author":"Williams","year":"2007","journal-title":"Brain"}],"container-title":["Frontiers in Aging Neuroscience"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnagi.2023.1229491\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,31]],"date-time":"2023-08-31T04:53:14Z","timestamp":1693457594000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnagi.2023.1229491\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,30]]},"references-count":48,"alternative-id":["10.3389\/fnagi.2023.1229491"],"URL":"https:\/\/doi.org\/10.3389\/fnagi.2023.1229491","relation":{},"ISSN":["1663-4365"],"issn-type":[{"value":"1663-4365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,30]]},"article-number":"1229491"}}